News

Josh Anderson, head of U.S. retina sales and marketing for Alcon, outlines what attendees will learn including product updates, new technologies, and practice management materials for ophthalmologists and their patients during the COVID-19 pandemic.

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

Ted Leng, MD, MS, Byers Eye Institute at Stanford, and medical advisor for Verana Health, talks about data insights for retinal surgeons. Steven D. Schwartz, MD, Stein Eye Institute, UCLA, highlights his AAO presentation, “New Insight into Real-World U.S. Injection Data."

Gene therapy for X-linked retinitis pigmentosa is achieving significant visual gains at 1 year mark.

During Day 1 of AAO 2020, Carl Awh, MD, discusses the Micro-Vacuum Pick, a device for peeling internal limiting membranes that's providing vitreoretinal surgeons an alternative to forceps during surgeries.

Prof. Marie-José Tassignon, past chief and chair, Department of Ophthalmology, Antwerp University and University Hospital Antwerp, Belgium, expands on her AAO presentation by providing an overview of her novel technique in performing a risk-free posterior capsulorhexis.

Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.

Anne L. Coleman, MD, president of the American Academy of Ophthalmology, offers a preview of its virtual 2020 annual meeting.

The University of California San Francisco brings its vision care and research facilities together at the UCSF Wayne and Gladys Valley Center for Vision.

The program is dedicated to the education of fellows and residents and offers a unique opportunity to share notable retina research with peers and mentors.

American Academy of Ophthalmology (AAO) President Anne L. Coleman, MD, PhD, offers a preview of what attendees can look forward to from the academy's 2020 virtual annual meeting — kicking off Nov. 13-15.

Manufacturers are stepping up to design products that will help maximize the safety and efficiency of intravitreal injection.

The benefit is robust across a variety of demographics and baseline disease characteristics, according to data.

Dietary macular pigments, which can now be measured directly and accurately, are hugely important in optimizing visual function, especially as we age.

A team of researchers has found that the diameter of retinal veins may be linked directly to the severity of COVID-19. Assessing the retinal veins may be a part of diagnosing and managing the disease.

Understanding the per-person cost differences with 3 key management strategies for a better-informed treatment selection

How this method of anesthesia may provide benefits to both the patient and physician

High-quality images can be useful for early diagnosis, prognosis, monitoring

Following trends by geographic variation in practice patterns, perceptions toward opioids, and patient population

To maintain treatment quality and patient and staff safety in the SARS-CoV-2 era, it is important to minimize clinic visits and maximize the use of imaging modalities. In addition, extending treatment intervals with longer-acting agents is key to maximizing safety and patients’ vision outcomes.

Euan S. Thomson, PhD, global president of ophthalmic devices at Carl Zeiss Meditec, talks about the “Zeiss Virtual Experience” during the 2020 EURETINA virtual meeting, and how attendees can navigate the booth to find the must-see products Zeiss is highlighting.

Lars Risby, international sales and training manager, Oculus Surgical, discusses how the global pandemic has re-prioritized production lines to enhance sterile product offerings and how the company is working with others in industry to improve overall product lines.

Dr Grazia Pertile, head of the Department of Ophthalmology, Sacrocuore Hospital, Negrar-Verona, Italy, reveals two courses that will be taking place at this year’s EURETINA.

Dr M.M. Alberto Pestano explains how optic neuropathy can present as a masquerade syndrome. He highlighted a case of unilateral infiltrative optic neuropathy that presented as a masquerade syndrome in a man with esophageal adenocarcinoma.

According to Dr Jose Ignacio Fernandez-Vigo, follow-ups can be affected by comorbidities, anxiety about injections, and long waits in the clinic

Krysten Williams, head of global marketing and education at Heidelberg Engineering, describes what’s new in multimodal imaging and how Heidelberg plays a role in it, the company’s virtual academy, and they're promoting the “dynamic visualization” of the entire eye.

Hamadi El-Ayari, vice president, sales and marketing at Geuder AG, divulges details about the numerous product introductions the company is planning at the 2020 EURETINA virtual conference.

Prof. Anat Lowenstein of Tel Aviv University, Israel, discusses the innovative moves towards incorporating head-wearable devices in surgical theatres and the importance of improving outcomes in the management of AMD patients with home monitoring, a field particularly noteworthy during the COVID-19 pandemic.

Dr Tunde Peto explains that the rate of blindness from diabetes continues to increase by 8% annually and the only way to prevent this may well rest with well-planned, evidence-based services.

A port delivery system with ranibizumab with dosing every 24 weeks has been shown in a Phase III trial to be equivalent to monthly intravitreal ranibizumab injection to treat neovascular age-related macular degeneration, according to Dr Carl Regillo, who reported on behalf of the Archway Trial investigators.